ERBB2 and breast cancer: Neoadjuvant chemotherapy (NAC) is increasingly being considered as an initial treatment option for local breast cancer (BC) patients [1], as it has demonstrated advantages such as early treatment of micrometastatic disease, the ability to reduce tumor burden, allowing more breast-conserving surgery (BCS) and the provision of tumor chemosensitivity information for future therapeutic management, especially useful in tumor subtypes like HER2+ and triple negative, for which antibody–drug conjugates and immunotherapy may be offered as additional adjuvant therapeutic management [2,3,4,5,6,7,8].